Abstract

Objective. To compare, “in a real world,” the performance of the most common composite activity indices in a cohort of PsA patients. Methods. A total of 171 PsA patients were involved. The following variables were evaluated: peripheral joint assessment, patient reported of pain, physician and patient assessments of disease activity, patient general health status, dactylitis digit count, Leeds Enthesitis Index, Health Assessment Questionnaire (HAQ), physical and mental component summary score of the Medical Outcome Survey (SF-36), Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR). To measure the disease activity, the Disease Activity Score (DAS28-ESR and DAS28-CRP), Simple Disease Activity Index (SDAI), Composite Psoriatic Disease Activity Index (CPDAI), disease activity in psoriatic arthritis (DAPSA), and Psoriatic Arthritis Disease Activity Score (PASDAS) have been calculated. The criteria for minimal disease activity (MDA) and remission were applied as external criterion. Results. The ROC were similar in all the composite measures. Only the CPDAI showed less discriminative ability. There was a high degree of correlation between all the indices (P < 0.0001). The highest correlations were between DAPSA and SDAI (rho = 0.996) and between DAPSA and DAS28-CRP (rho = 0.957). CPDAI, DAPSA, and PASDAS had the most stringent definitions of remission and MDA category. DAS28-ESR and DAS28-CRP had the highest proportions in remission and MDA. Conclusions. Although a good concurrent validity and discriminant capacity of six disease activity indices were observed, the proportions of patients classified in the disease activity levels differed. In particular, the rate of patients in remission was clearly different among the respective indices.

Highlights

  • Psoriatic arthritis (PsA) is a chronic inflammatory disease with widely variable intra- and interindividual clinical course and outcome

  • LR: likelihood ratio; 95% CI: 95% confidence intervals; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; SF36 PCS: physical component summary score of the Medical Outcome Survey Short Form-36; SF36MCS: mental component summary score of the Medical Outcome Survey Short Form-36; DLQI: Dermatology Life Quality Index; HAQ: Health Assessment Questionnaire; DAS28: 28-Disease Activity Score; Simple Disease Activity Index (SDAI): Simplified Disease Activity Index; CPDAI: Composite Psoriatic Disease Activity Index; DAPSA: disease activity in psoriatic arthritis; PASDAS: Psoriatic Arthritis Disease Activity Score

  • The core domains and tools to be used both in clinical trials and care in PsA patients have been identified by GRAPPA and preliminary validation was obtained through the Outcome Measures in Rheumatology Clinical Trials (OMERACT) process [13]

Read more

Summary

Introduction

Psoriatic arthritis (PsA) is a chronic inflammatory disease with widely variable intra- and interindividual clinical course and outcome. Its heterogeneity is such that the term “psoriatic disease” has been recently suggested to encompass the involvement of different tissue and organ levels. The prevalence among patients with psoriasis was reported as approximately 6.2% to 34.4% [1, 2]. It is largely known that an early and aggressive control of disease activity results in significantly better clinical, functional, and radiographic outcomes in patients with rheumatoid arthritis (RA) [5]. A similar paradigm of “treating-to-target” or “minimal disease activity” (MDA) has not yet been carefully established for PsA, it is clear that it is becoming the current challenge in the management of PsA [6, 7]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call